一种非竞争性 BACE1 抑制剂 TAK-070 可改善阿尔茨海默病小鼠模型中的 Abeta 病理和行为缺陷。
A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.
机构信息
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Yodogawa-ku, Osaka 532-8686, Japan.
出版信息
J Neurosci. 2010 Aug 18;30(33):11157-66. doi: 10.1523/JNEUROSCI.2884-10.2010.
Abstract
We discovered a nonpeptidic compound, TAK-070, that inhibited BACE1, a rate-limiting protease for the generation of Abeta peptides that are considered causative for Alzheimer's disease (AD), in a noncompetitive manner. TAK-070 bound to full-length BACE1, but not to truncated BACE1 lacking the transmembrane domain. Short-term oral administration of TAK-070 decreased the brain levels of soluble Abeta, increased that of neurotrophic sAPPalpha by approximately 20%, and normalized the behavioral impairments in cognitive tests in Tg2576 mice, an APP transgenic mouse model of AD. Six-month chronic treatment decreased cerebral Abeta deposition by approximately 60%, preserving the pharmacological efficacy on soluble Abeta and sAPPalpha levels. These results support the feasibility of BACE1 inhibition with a noncompetitive inhibitor as disease-modifying as well as symptomatic therapy for AD.
摘要
我们发现一种非肽类化合物 TAK-070，它以非竞争性方式抑制 BACE1，BACE1 是产生被认为是阿尔茨海默病（AD）病因的 Abeta 肽的限速蛋白酶。TAK-070 与全长 BACE1 结合，但不与缺乏跨膜结构域的截断 BACE1 结合。短期口服 TAK-070 可降低大脑中可溶性 Abeta 的水平，使神经营养性 sAPPalpha 的水平增加约 20%，并使 Tg2576 小鼠（AD 的 APP 转基因小鼠模型）认知测试中的行为障碍正常化。6 个月的慢性治疗可使大脑中的 Abeta 沉积减少约 60%，同时保持对可溶性 Abeta 和 sAPPalpha 水平的药效。这些结果支持使用非竞争性抑制剂抑制 BACE1 作为 AD 的疾病修饰和症状治疗的可行性。
相似文献
1
A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.
J Neurosci. 2010 Aug 18;30(33):11157-66. doi: 10.1523/JNEUROSCI.2884-10.2010.
2
Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
J Neurosci. 2015 Apr 29;35(17):6931-6. doi: 10.1523/JNEUROSCI.2262-14.2015.
3
BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
Acta Neuropathol. 2018 May;135(5):695-710. doi: 10.1007/s00401-017-1804-9. Epub 2018 Jan 11.
4
AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.
J Neurosci. 2013 Jun 12;33(24):10075-84. doi: 10.1523/JNEUROSCI.1165-13.2013.
5
Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting β/γ-Secretases Activity and Enhancing α-Secretases.
Curr Alzheimer Res. 2018;15(11):1045-1052. doi: 10.2174/1567205015666180702105740.
6
Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice.
Eur J Neurosci. 2010 Jan;31(1):110-8. doi: 10.1111/j.1460-9568.2009.07031.x. Epub 2009 Dec 21.
7
[Effects of huannao yicong recipe extract on the learning and memory and related factors of Abeta generation in the brain of APP transgenic mice].
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Jan;33(1):90-4.
8
The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
J Alzheimers Dis. 2011;26(2):387-408. doi: 10.3233/JAD-2011-110101.
9
Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model.
Neurobiol Aging. 2012 Dec;33(12):2903-19. doi: 10.1016/j.neurobiolaging.2012.02.016. Epub 2012 Mar 27.
10
Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Neurobiol Dis. 2016 Jan;85:187-205. doi: 10.1016/j.nbd.2015.11.005. Epub 2015 Nov 10.
引用本文的文献
1
Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti-amyloid therapies.
Alzheimers Dement. 2024 Feb;20(2):1459-1464. doi: 10.1002/alz.13566. Epub 2023 Dec 12.
2
ARL6IP1 mediates small-molecule-induced alleviation of Alzheimer pathology through FXR1-dependent BACE1 translation initiation.
Proc Natl Acad Sci U S A. 2023 May 30;120(22):e2220148120. doi: 10.1073/pnas.2220148120. Epub 2023 May 22.
3
The microRNA-455 Null Mouse Has Memory Deficit and Increased Anxiety, Targeting Key Genes Involved in Alzheimer's Disease.
Int J Mol Sci. 2022 Jan 5;23(1):554. doi: 10.3390/ijms23010554.
4
Amyloid Beta Dynamics in Biological Fluids-Therapeutic Impact.
J Clin Med. 2021 Dec 20;10(24):5986. doi: 10.3390/jcm10245986.
5
MicroRNAs Regulating Autophagy in Neurodegeneration.
Adv Exp Med Biol. 2021;1208:191-264. doi: 10.1007/978-981-16-2830-6_11.
6
Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment.
Int J Mol Sci. 2021 May 24;22(11):5549. doi: 10.3390/ijms22115549.
7
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.
Mol Neurodegener. 2020 Sep 14;15(1):53. doi: 10.1186/s13024-020-00393-5.
8
Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease.
Degener Neurol Neuromuscul Dis. 2014 Jan 22;4:1-19. doi: 10.2147/DNND.S41056. eCollection 2014.
9
Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer's disease model mice.
PLoS One. 2019 Jul 15;14(7):e0219691. doi: 10.1371/journal.pone.0219691. eCollection 2019.
10
MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation.
Brain. 2019 Jan 1;142(1):176-192. doi: 10.1093/brain/awy305.
本文引用的文献
1
The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex.
J Neurosci. 2010 Apr 7;30(14):4833-44. doi: 10.1523/JNEUROSCI.5221-09.2010.
2
Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation.
J Biol Chem. 2009 May 1;284(18):11863-72. doi: 10.1074/jbc.M807345200. Epub 2009 Feb 27.
3
First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.
J Pharmacol Exp Ther. 2009 Jan;328(1):131-40. doi: 10.1124/jpet.108.143628. Epub 2008 Oct 14.
4
Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
Med Res Rev. 2009 Mar;29(2):295-338. doi: 10.1002/med.20132.
5
A closer look at alpha-secretase.
Curr Alzheimer Res. 2008 Apr;5(2):179-86. doi: 10.2174/156720508783954668.
6
BACE1 structure and function in health and Alzheimer's disease.
Curr Alzheimer Res. 2008 Apr;5(2):100-20. doi: 10.2174/156720508783954758.
7
Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice.
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5585-90. doi: 10.1073/pnas.0710373105. Epub 2008 Apr 2.
8
Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse.
J Neurosci Res. 2008 May 15;86(7):1615-25. doi: 10.1002/jnr.21601.
9
In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
J Pharmacol Exp Ther. 2008 Mar;324(3):957-69. doi: 10.1124/jpet.107.130039. Epub 2007 Dec 21.
10
Beta-amyloid modulation of synaptic transmission and plasticity.
J Neurosci. 2007 Oct 31;27(44):11832-7. doi: 10.1523/JNEUROSCI.3478-07.2007.
Zotero 插件